- Novartis recently secured European Commission approval for Cosentyx in adults with polymyalgia rheumatica after inadequate or relapsing steroid treatment, supported by Phase III REPLENISH data and flexible dosing up to 300 mg.
- The move pushes Novartis deeper into immunology, providing a first-in-class IL-17A option in a steroid-dependent condition and adding another branded therapy where long courses of treatment and specialist prescribing can be commercially important.
- We will look at how Novartis' investment narrative is affected by Cosentyx's new PMR approval and its broader immunology ambitions.
Scan how Novartis fits into a wider basket of quality opportunities by lining it up against our hand picked 191 high quality undervalued stocks that combine cash flow strength with balance sheet resilience.
Novartis Investment Narrative Recap
To own Novartis you need to believe its mix of patent protected drugs, a broad late stage pipeline and a reliable dividend can outweigh pressure from patent losses, pricing reforms and heavier use of generics. The Cosentyx PMR approval supports that thesis at the margin by extending an existing brand into another immune condition where treatment options have been limited.
In the near term, the key swing factor remains how quickly revenue from newer therapies and immunology assets offsets erosion around older products like Entresto as generics emerge and pricing pressure builds. The biggest risk is that competition and reimbursement constraints reduce the economic payoff from these launches, leaving earnings more exposed to loss of exclusivity headwinds.
The fresh Cosentyx PMR approval in Europe appears most relevant here because it directly feeds into Novartis immunology ambitions. It adds another line item where prescribing is likely concentrated in specialists and often chronic. This can matter when the group is trying to keep top line momentum while earnings are forecast to grow about 10.6% a year.
Execution risk remains a consideration. Cosentyx already faces competitive and potential biosimilar pressure, and broader policy shifts in Europe, China and the US may limit pricing flexibility on new indications. The approval still acts as a useful proof point that the R&D engine is converting Phase III work into real products. This is important when pipeline setbacks have raised questions about longer term growth contributions.
Novartis' current analyst script points to revenues of $67.6b and earnings of $18.7b by 2029, based on 6.0% yearly top line growth and an increase in earnings of about $5.9b from $12.8b today.
Uncover why Novartis' fair value indicates a 4% potential downside to its current price, leaving little room for error.
Exploring Other Perspectives
One alternate view anchors on manufacturing and cost risk rather than topline promise. In that script, heavy spending on radioligand and biologics capacity could squeeze Novartis margins, which helps explain why the most cautious analysts were only pencilling in about $64.3b of revenue and $16.1b of earnings by 2029 before this Cosentyx PMR approval. Those expectations show how wide opinion runs, so treat this news as a cue to compare several narratives, not to assume analysts will stand still.
Explore 3 other Novartis fair value estimates, including one that suggests it could be worth just CHF 123.56.
Decide For Yourself
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Novartis research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Novartis. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Novartis' overall financial health at a glance.
Looking For More Investment Ideas Beyond Novartis?
If the Cosentyx news has prompted you to reassess Novartis, it can help to compare it against other opportunities that fit clear, rules based filters. The Simply Wall St screener lets you line up different types of companies quickly so you can focus on the ones that suit your risk profile and income needs.
- For investors who want high income from equities and care about stability, review companies in the 224 dividend fortresses that screen for yield and resilience.
- If capital preservation matters more than chasing big swings, consider the 222 resilient stocks with low risk scores to zero in on businesses with lower risk scores.
- When you want strong fundamentals and balance sheet strength to anchor a portfolio, start with the list of solid balance sheet and fundamentals (204 results) and see which stocks fit that profile.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com